SecBot SecBot
SECBOTREPLAY Home › Report › MLYS

MLYS · Mineralys Therapeutics announced that new data from its Phase 3…

Mineralys Therapeutics, Inc. · PRESS-RELEASE filed May 18, 2026 at 16:05 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed May 18, 2026 at 16:05 ET

Mineralys Therapeutics announced that new data from its Phase 3 LAUNCH-HTN trial of lorundrostat in patients with uncontrolled hypertension and chronic kidney disease will be presented at ESH 2026 on May 30. The oral presentation highlights the drug's efficacy and safety profile, supporting its NDA under FDA review. This is a routine scientific conference presentation with no new clinical data released in the filing, making it a modest positive catalyst for awareness but not a material event.

  • Oral presentation of Phase 3 LAUNCH-HTN data at ESH 2026 on May 30, 2026
  • Trial enrolled adults with uncontrolled hypertension on 2-5 medications, randomized to placebo, lorundrostat 50 mg, or 50 mg with optional up-titration to 100 mg
  • Primary endpoint: change from baseline in systolic BP at 6 weeks vs placebo
  • NDA for lorundrostat is under FDA review

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access